Gadolinium contrast agents- challenges and opportunities of a multidisciplinary approach: Literature review

Kang, 2022, Preparation of magnetic resonance contrast agent gadolinium-containing organic nanoparticles and their electrochemical behavior investigation, Int. J. Electrochem. Sci., vol. 17, 1, 10.20964/2022.07.62 Cheong, 2022, Gadolinium-based contrast agents: updates and answers to typical questions regarding gadolinium use, Tex. Hear. Inst. J., vol. 49, 7 Chanana, 2022, The effect of magnetic field gradient and gadolinium-based mri contrast agent dotarem on mouse macrophages, Cells, vol. 11, 757, 10.3390/cells11050757 Huang, 2021, Sericin-based gadolinium nanoparticles as synergistically enhancing contrast agents for pH-responsive and tumor targeting magnetic resonance imaging, Mater. Des., vol. 203, 10.1016/j.matdes.2021.109600 Al-Tell, 2019, Justification of urgent brain CT examinations at medium size hospital, Jerusalem, Atlas J. Biol., 655, 10.5147/ajb.v0i0.213 Oglat, 2018, Chemical items used for preparing tissue-mimicking material of wall-less flow phantom for doppler ultrasound imaging, J. Med. Ultrasound, vol. 26, 123, 10.4103/JMU.JMU_13_17 Ammar, 2018, Characterization and construction of a robust and elastic wall-less flow phantom for high pressure flow rate using doppler ultrasound applications, Nat. Eng. Sci., vol. 3, 359 Mahmood, 2022, Safety of gadolinium based contrast agents in magnetic resonance imaging-guided radiotherapy – an investigation of chelate stability using relaxometry, Phys. Imaging Radiat. Oncol., vol. 21, 96, 10.1016/j.phro.2022.02.015 Cobanoglu, 2022, Assessment of genetic damage induced by gadolinium-based radiocontrast agents, J. Trace Elem. Med. Biol., vol. 70 Oglat, 2020, Artifacts in diagnostic ultrasonography, J. Vasc. Ultrasound, vol. 44, 212, 10.1177/1544316720923937 Ahmad, 2022, Ability of MRI diagnostic value to detect the evidence of physiotherapy outcome measurements in dealing with calf muscles tearing, J. Med. Clin. Res. Rev., vol. 6, 6, 10.33425/2639-944X.1292 Meng, 2022, Responsive gadolinium(III) complex-based small molecule magnetic resonance imaging probes: Design, mechanism and application, Coord. Chem. Rev., vol. 457, 10.1016/j.ccr.2021.214398 Davies, 2022, Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration, Arch. Toxicol., vol. 96, 403, 10.1007/s00204-021-03189-8 Ahmad, 2021, Agarose and wax tissue-mimicking phantom for dynamic magnetic resonance imaging of the liver, J. Med. - Clin. Res. Rev., vol. 5 Ban, 2021, Modern heavyweight concrete shielding: Principles, industrial applications and future challenges; review, J. Build. Eng., vol. 39 Ahmad, 2020, A recent short review in non-invasive magnetic resonance imaging on assessment of HCC Stages: MRI findings and pathological diagnosis, J. Gastroenterol. Hepatol. Res., vol. 9, 3113, 10.17554/j.issn.2224-3992.2020.09.881 Ahmad, 2019, Current status regarding tumour progression, surveillance, diagnosis, staging, and treatment Of HCC a literature review, J. Gastroenterol. Hepatol. Res, vol. 8, 2841, 10.17554/j.issn.2224-3992.2019.07.814 Makhamrah, 2023, Internal auditory canal (IAC) and cerebellopontine angle (CPA): comparison between T2-weighted SPACE and 3D-CISS sequences at 1.5T, Radiat. Phys. Chem., vol. 206 Zheng, 2022, A risk prediction model for contrast-induced nephropathy associated with gadolinium-based contrast agents, Ren. Fail., vol. 44, 741, 10.1080/0886022X.2022.2069579 Lohrke, 2022, Preclinical profile of gadoquatrane, Invest. Radiol., vol. 57, 629, 10.1097/RLI.0000000000000889 Clough, 2019, Ligand design strategies to increase stability of gadolinium-based magnetic resonance imaging contrast agents, Nat. Commun., 1 O. Makhamrah, M.S. Ahmad, and M. Hjouj, Evaluation of Liver Phantom for Testing of the Detectability Multimodal for Hepatocellular Carcinoma, in Proceedings of the 2019 2nd International Conference on Digital Medicine and Image Processing, Nov. 2019, pp. 17–21. doi: 10.1145/3379299.3379307. Ahmad, 2021, Hepatocellular carcinoma liver dynamic phantom for MRI, MR Imaging Intern. Audit. Canal Inn. Ear 3T Comp. 3D Driven Equilib. 3D Balanc. Fast F. Echo Seq., vol. 188 Jakobsen, 2021, Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study, BMC Med. Imaging, vol. 21, 74, 10.1186/s12880-021-00600-9 Patil, 2020, Single- and multi-arm gadolinium MRI contrast agents for targeted imaging of glioblastoma, Int. J. Nanomed., vol. Volume 15, 3057, 10.2147/IJN.S238265 A.M. Iordache et al., The incidence of skin lesions in contrast media- induced chemical hypersensitivity, pp. 1113–1124, 2019, doi: 10.3892/etm.2018.7056. Ahmad, 2020, Dynamic hepatocellular carcinoma model within a liver phantom for multimodality imaging, Eur. J. Radiol. Open, vol. 7, 10.1016/j.ejro.2020.100257 Ahmad, 2020, Chemical characteristics, motivation and strategies in choice of materials used as liver phantom: a literature review, J. Med. Ultrasound, vol. 28, 115 Ahmad, 2021, Multimodal imaging of hepatocellular carcinoma using dynamic liver phantom, intechopen, no. Tour., 13 Azizian, 2012, Synthesis route and three different core-shell impacts on magnetic characterization of gadolinium oxide-based nanoparticles as new contrast agents for molecular magnetic resonance imaging, Nanoscale Res. Lett., vol. 7, 1, 10.1186/1556-276X-7-549 Shahid, 2022, Use of real-life safety data from international pharmacovigilance databases to assess the importance of symptoms associated with gadolinium exposure, Invest. Radiol., vol. 57, 664, 10.1097/RLI.0000000000000880 E.M. Gale and P. Caravan, Gadolinium-Free Contrast Agents for Magnetic Resonance Imaging of the Central Nervous System, pp. 395–397, 2018, doi: 10.1021/acschemneuro.8b00044. Bi, 2022, Gadolinium deposition in the brain is related to various contrast agents: a matched case–control study, Clin. Radiol., vol. 77, 299, 10.1016/j.crad.2021.12.020 Hojreh, 2020, Subsequent MRI of pediatric patients after an adverse reaction to Gadolinium-based contrast agents, PLoS One, vol. 15, 10.1371/journal.pone.0230781 V.A. Athavale, Athavale VA, Application of Artificial Intelligence in Magnetic Resonance Imaging to reduce Gadolinium accumulation in patients with multiple sclerosis: A Review Application of artificial intelligence in magnetic resonance imaging to reduce gadolinium acc, vol. 2, no. 1, pp. 478–490, 2022, doi: 10.52152/spr/2022.157. gadolinium deposition after administration of gadolinium ‑ based contrast agents Kanda, 2016, Brain gadolinium deposition after administration of gadolinium ‑ based contrast agents, Jpn. J. Radiol., vol. 34 Uosef, 2020, Side effects of gadolinium MRI contrast agents, Pediatr. i Med. Rodz., vol. 16, 49, 10.15557/PiMR.2020.0008 Rogosnitzky, 2016, Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms, BioMetals, vol. 29, 365, 10.1007/s10534-016-9931-7 Gallo-Bernal, 2022, Nephrogenic systemic fibrosis in patients with chronic kidney disease after the use of gadolinium-based contrast agents: a review for the cardiovascular imager, Diagnostics, vol. 12, 1816, 10.3390/diagnostics12081816 A. Balachandran, P. Kala, S. Ashwathappa, M. Varunya, R. Kollu, and H.V. Ramprakash, O riginal R esearch A rticle Gadolinium-based Contrast Agents: Evaluation of Effect On Renal Function Parameters, vol. 3, no. 1, pp. 166–169, 2018. RGadolinium-based contrast agent accumulation and toxicity: An updateamalho, 2016, Gadolinium-based contrast agent accumulation and toxicity: an update, Am. J. Neuroradiol., vol. 37, 1192, 10.3174/ajnr.A4615 Green, 2022, The Effect of Gadolinium-Based Contrast Agents on Longitudinal Changes of Magnetic Resonance Imaging Signal Intensities and Relaxation Times in the Aging Rat Brain, Invest. Radiol., vol. 57, 453, 10.1097/RLI.0000000000000857 Grueber, 2021, Skin test results and cross-reactivity patterns in IgE- And T-cell-mediated allergy to gadolinium-based contrast agents, Allergy, Asthma Immunol. Res, vol. 13, 933, 10.4168/aair.2021.13.6.933 Layne, 2018, Gadolinium deposition and the potential for toxicological sequelae – a literature review of issues surrounding gadolinium‐based contrast agents, Br. J. Clin. Pharmacol., vol. 84, 2522, 10.1111/bcp.13718 Morcos, 2008, Extracellular gadolinium contrast agents: differences in stability, Eur. J. Radiol., vol. 66, 175, 10.1016/j.ejrad.2008.01.025 Lange, 2021, Nephrogenic systemic fibrosis as a complication after gadolinium-containing contrast agents: a rapid review, Int. J. Environ. Res. Public Health, vol. 18, 3000, 10.3390/ijerph18063000 Patel, 2020, Safety of intrathecal administration of gadolinium-based contrast agents: a systematic review and meta-analysis, Radiology, vol. 297, 75, 10.1148/radiol.2020191373 Moser, 2018, High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: comparison between gadobutrol and linear gadolinium-based contrast agents, Am. J. Neuroradiol., vol. 39, 421, 10.3174/ajnr.A5538 Yao, 2022, Gadolinium retention in the brain of mother and pup mouse: effect of pregnancy and repeated administration of <scp>gadolinium‐based</scp> contrast agents, J. Magn. Reson. Imaging, vol. 56, 835, 10.1002/jmri.28086 Lie, 2022, The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis, Eur. Radiol., vol. 32, 3576, 10.1007/s00330-021-08405-8 Forslin, 2019, Gadolinium retention in the brain: An MRI relaxometry study of linear and macrocyclic gadolinium-based contrast agents in multiple sclerosis, Am. J. Neuroradiol., vol. 40, 1265, 10.3174/ajnr.A6112 X.T. Granberg, Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study, 2017. Ranga, 2017, Gadolinium based contrast agents in current practice: risks of accumulation and toxicity in patients with normal renal function, Indian J. Radiol. Imaging, vol. 27, 141, 10.4103/0971-3026.209212 Gallo, 2020, Peptide-based soft hydrogels modified with gadolinium complexes as MRI contrast agents, Pharmaceuticals, vol. 13, 19, 10.3390/ph13020019 Fatima, 2021, Recent advances in gadolinium based contrast agents for bioimaging applications, Nanomaterials, vol. 11, 2449, 10.3390/nano11092449 Bara, 2022, Hypersensitivity to gadolinium-based contrast media, vol. 3 Uhlig, 2019, Acute adverse events in cardiac MR imaging with gadolinium-based contrast agents: results from the European Society of Cardiovascular Radiology ( ESCR) MRCT Registry in 72, 839 Patients Am. Coll. Radiol., 3686 Soloff, 2020, Safety of gadolinium-based contrast agents in patients with stage 4 and 5 chronic kidney disease: a radiologist’s perspective, Kidney360, vol. 1, 123, 10.34067/KID.0000502019 S. Maripuri and K.L. Johansen, Risk of Gadolinium-Based Contrast Agents in Chronic Kidney Disease — Is Zero Good Enough ?, pp. 1–2, 2019, doi: 10.1002/jmri.25625. Runge, 2018, Dechelation (Transmetalation): consequences and safety concerns with the linear gadolinium-based contrast agents, in view of recent health care rulings by the EMA (Europe), FDA (United States), and PMDA (Japan), Invest. Radiol., vol. 53, 571, 10.1097/RLI.0000000000000507 Dekkers, 2018, Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European medicines agency, Eur. Radiol., vol. 28, 1579, 10.1007/s00330-017-5065-8 Among, 2021, HHS Public Access, vol. 55, 636 Kartamihardja, 2021, The role of ferrous ion in the effect of the gadolinium-based contrast agents (GBCA) on the purkinje cells arborization: an in vitro study, Diagnostics, vol. 11, 2310, 10.3390/diagnostics11122310 Shah, 2019, Use of gadolinium contrast agents in paediatric population: donald rumsfeld meets hippocrates!, Br. J. Radiol., vol. 92, 10.1259/bjr.20180746 Naganawa, 2021, Relationship between time-dependent signal changes in parasagittal perivenous cysts and leakage of gadolinium-based contrast agents into the subarachnoid space, Magn. Reson. Med. Sci., vol. 20, 378, 10.2463/mrms.mp.2020-0138 T. Frenzel, C. Apte, G. Jost, L. Schöckel, J. Lohrke, and H. Pietsch, Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents Comparative Study in Rats, vol. 52, no. 7, pp. 18–20, 2017, doi: 10.1097/RLI.0000000000000352. R.J. Mcdonald et al., Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging1, vol. 000, no. 0, pp. 1–11, 2015. J.K. Richter, H. Von Tengg-kobligk, J.T. Heverhagen, and V.M. Runge, Gadolinium-Based MRI Contrast Agents Induce Mitochondrial Toxicity and Cell Death in Human Neurons, and Toxicity Increases With Reduced Kinetic Stability of the Agent, vol. 54, no. 8, pp. 453–463, 2019, doi: 10.1097/RLI.0000000000000567. Burke, 2016, Self-reported gadolinium toxicity: a survey of patients with chronic symptoms, Magn. Reson. Imaging, vol. 34, 1078, 10.1016/j.mri.2016.05.005 Nucera, 2022, Contrast medium hypersensitivity: a large Italian study with long-term follow-up, Biomedicines, vol. 10, 759, 10.3390/biomedicines10040759 Nucera, 2021, Gadolinium-based contrast agents hypersensitivity: a case series, J. Asthma Allergy, vol. Volume 14, 241, 10.2147/JAA.S295748 Rudnick, 2020, Use of gadolinium-based contrast agents in patients with severe renal impairment. absence of risk versus caution: a nephrologist’s perspective, Kidney360, vol. 1, 433, 10.34067/KID.0003022020 A.R.B. Study, Are Gadolinium-Based Contrast Media Nephrotoxic ?”. Harvey, 2019, Gadolinium deposition disease: a new risk management threat, J. Am. Coll. Radiol., vol. 17, 546, 10.1016/j.jacr.2019.11.009 Semelka, 2016, Gadolinium deposition disease: Initial description of a disease that has been around for a while, Magn. Reson. Imaging, vol. 34, 1383, 10.1016/j.mri.2016.07.016 Fraum, 2017, Gadolinium-based contrast agents: a comprehensive risk assessment, J. Magn. Reson. Imaging, vol. 46, 338, 10.1002/jmri.25625 Bird, 2019, First-trimester exposure to gadolinium-based contrast agents: a utilization study of 4.6 Million U.S. Pregnancies, Radiology, vol. 293, 193, 10.1148/radiol.2019190563 Ray, 2016, Association between MRI exposure during pregnancy and fetal and childhood outcomes, JAMA, vol. 316, 952, 10.1001/jama.2016.12126 Kanda, 2019, The new restrictions on the use of linear gadolinium-based contrast agents in Japan, Magn. Reson. Med. Sci., vol. 18, 1, 10.2463/mrms.e.2017-0176 Robert, 2020, Contrast-to-dose relationship of gadopiclenol, an MRI macrocyclic gadolinium-based contrast agent, compared with gadoterate, gadobenate, and gadobutrol in a rat brain tumor model, Radiology, vol. 294, 117, 10.1148/radiol.2019182953 Tweedle, 2020, Next-Generation MRI contrast agents: still including gadolinium, Radiology, vol. 294, 127, 10.1148/radiol.2019192113 M. Le Fur, P. Caravan, and M.G. Hospital, The biological fate of gadolinium-based MRI contrast agents: a call to action for bioinorganic chemists, vol. 11, no. 2, pp. 240–254, 2020, doi: 10.1039/c8mt00302e.The. Ben Salem, 2021, Determination of rare earth elements in gadolinium-based contrast agents by ICP-MS, Talanta, vol. 221 Birka, 2016, Investigating the stability of gadolinium based contrast agents towards UV radiation, Water Res, vol. 91, 244, 10.1016/j.watres.2016.01.012